RSI Overbought Stocks
ETON is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
ETON PHARMACEUTICALS INC (ETON) Stock Price & Overview
NASDAQ:ETON • US29772L1089
Current stock price
24.99 USD
-0.37 (-1.46%)
At close:
24.99 USD
0 (0%)
After Hours:
The current stock price of ETON is 24.99 USD. Today ETON is down by -1.46%. In the past month the price increased by 45%. In the past year, price increased by 111.24%.
ETON Key Statistics
52-Week Range11.0867 - 25.99
Current ETON stock price positioned within its 52-week range.
1-Month Range16.135 - 25.99
Current ETON stock price positioned within its 1-month range.
- Market Cap
- 670.232M
- P/E
- N/A
- Fwd P/E
- 27.12
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
ETON Stock Performance
Today
-1.46%
1 Week
+6.57%
1 Month
+45.00%
3 Months
+53.69%
Longer-term
6 Months +25.39%
1 Year +111.24%
2 Years +614.00%
3 Years +588.43%
5 Years +187.90%
10 Years N/A
ETON Stock Chart
ETON Stock Screens
ETON currently appears in the following ChartMill screener lists.
ETON Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ETON. When comparing the yearly performance of all stocks, ETON is one of the better performing stocks in the market, outperforming 94.31% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ETON Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ETON. The financial health of ETON is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ETON Earnings
On March 19, 2026 ETON reported an EPS of 0.06 and a revenue of 21.28M. The company missed EPS expectations (-34.64% surprise) and beat revenue expectations (1.38% surprise).
Next Earnings DateMay 11, 2026
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS Reported$0.06
Revenue Reported21.281M
EPS Surprise -34.64%
Revenue Surprise 1.38%
ETON Forecast & Estimates
9 analysts have analysed ETON and the average price target is 38.42 USD. This implies a price increase of 53.74% is expected in the next year compared to the current price of 24.99.
For the next year, analysts expect an EPS growth of 2403.49% and a revenue growth 32.81% for ETON
Analysts
Analysts82.22
Price Target38.42 (53.74%)
EPS Next Y2403.49%
Revenue Next Year32.81%
ETON Groups
Sector & Classification
ETON Financial Highlights
Over the last trailing twelve months ETON reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 71.43% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-6.68M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.39% | ||
| ROE | -28.89% | ||
| Debt/Equity | 1.31 |
Chartmill High Growth Momentum
EPS Q2Q%400%
Sales Q2Q%82.72%
EPS 1Y (TTM)71.43%
Revenue 1Y (TTM)N/A
ETON Ownership
Ownership
Inst Owners59.87%
Shares26.82M
Float25.64M
Ins Owners4.39%
Short Float %7.4%
Short Ratio5.82
ETON Latest News, Press Relases and Analysis
15 days ago - By: Chartmill
ETON Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ETON
Company Profile
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 31 full-time employees. The company went IPO on 2018-11-09. The firm has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Company Info
IPO: 2018-11-09
ETON PHARMACEUTICALS INC
21925 W Field Pkwy Ste 235
Deer Park ILLINOIS 60010 US
CEO: Sean E. Brynjelsen
Employees: 31
Phone: 18004831140
ETON PHARMACEUTICALS INC / ETON FAQ
What does ETON do?
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 31 full-time employees. The company went IPO on 2018-11-09. The firm has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Can you provide the latest stock price for ETON PHARMACEUTICALS INC?
The current stock price of ETON is 24.99 USD. The price decreased by -1.46% in the last trading session.
Does ETON PHARMACEUTICALS INC pay dividends?
ETON does not pay a dividend.
How is the ChartMill rating for ETON PHARMACEUTICALS INC?
ETON has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of ETON PHARMACEUTICALS INC (ETON)?
ETON PHARMACEUTICALS INC (ETON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).
What is ETON PHARMACEUTICALS INC worth?
ETON PHARMACEUTICALS INC (ETON) has a market capitalization of 670.23M USD. This makes ETON a Small Cap stock.
What is the next earnings date for ETON stock?
ETON PHARMACEUTICALS INC (ETON) will report earnings on 2026-05-11.